{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:04:45Z","timestamp":1791644685845,"version":"4.3.4"},"reference-count":17,"publisher":"Society of Nuclear Medicine","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2024,8,7]]},"published-print":{"date-parts":[[2024,11]]},"DOI":"10.2967\/jnumed.124.267723","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T11:57:24Z","timestamp":1726747044000},"page":"1724-1730","source":"Crossref","is-referenced-by-count":21,"title":["Initial Experience with [\n                    <sup>177<\/sup>\n                    Lu]Lu-PSMA-617 After Regulatory Approval for Metastatic Castration-Resistant Prostate Cancer: Efficacy, Safety, and Outcome Prediction"],"prefix":"10.2967","volume":"65","author":[{"given":"Andrei","family":"Gafita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Voter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somya","family":"Shesadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avery","family":"Spitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine H.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Markowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin G.","family":"Pomper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Cahid","family":"Civelek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Carducci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel R.","family":"Denmeade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth J.","family":"Pienta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Channing J.","family":"Paller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilja B.","family":"Solnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"key":"2025060410401057000_65.11.1724.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2025060410401057000_65.11.1724.2","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","article-title":"PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial","volume":"23","author":"Buteau","year":"2022","journal-title":"Lancet Oncol."},{"key":"2025060410401057000_65.11.1724.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00274-6"},{"key":"2025060410401057000_65.11.1724.4","doi-asserted-by":"crossref","unstructured":"Hofman MS Emmett L Sandhu S . Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. Lancet Oncol. 2024;25:99\u2013107.","DOI":"10.1016\/S1470-2045(23)00529-6"},{"key":"2025060410401057000_65.11.1724.5","doi-asserted-by":"crossref","first-page":"1054497","DOI":"10.3389\/fonc.2022.1054497","article-title":"Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: opportunities for integration and pitfalls to interpretation","volume":"12","author":"Kwan","year":"2022","journal-title":"Front Oncol."},{"key":"2025060410401057000_65.11.1724.6","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.euros.2023.08.007","article-title":"Circulating tumour DNA biomarkers associated with outcomes in metastatic prostate cancer treated with lutetium-177-PSMA-617","volume":"57","author":"Crumbaker","year":"2023","journal-title":"Eur Urol Open Sci."},{"key":"2025060410401057000_65.11.1724.7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.euros.2023.05.008","article-title":"AR and PI3K genomic profiling of cell-free DNA can identify poor responders to lutetium-177-PSMA among patients with metastatic castration-resistant prostate cancer","volume":"53","author":"Vanwelkenhuyzen","year":"2023","journal-title":"Eur Urol Open Sci."},{"key":"2025060410401057000_65.11.1724.8","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266167"},{"key":"2025060410401057000_65.11.1724.9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702"},{"key":"2025060410401057000_65.11.1724.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2102953\/SUPPL_FILE\/NEJMOA2102953_DISCLOSURES.PDF"},{"key":"2025060410401057000_65.11.1724.11","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265986"},{"key":"2025060410401057000_65.11.1724.12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30408-5"},{"key":"2025060410401057000_65.11.1724.13","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.eururo.2018.11.016","article-title":"Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer","volume":"75","author":"Heck","year":"2019","journal-title":"Eur Urol."},{"key":"2025060410401057000_65.11.1724.14","doi-asserted-by":"crossref","first-page":"S1324","DOI":"10.1016\/j.annonc.2023.10.085","article-title":"LBA13 phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore) [abstract]","volume":"34(suppl 2)","author":"Sartor","year":"2023","journal-title":"Ann Oncol."},{"key":"2025060410401057000_65.11.1724.15","doi-asserted-by":"crossref","first-page":"TPS210","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS210","article-title":"PSMAddition: a phase 3 trial to compare treatment with 177Lu-PSMA-617 plus standard of care (SOC) versus SOC alone in patients with metastatic hormone-sensitive prostate cancer [abstract]","volume":"40","author":"Sartor","year":"2022","journal-title":"J Clin Oncol."},{"key":"2025060410401057000_65.11.1724.16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.240242"},{"key":"2025060410401057000_65.11.1724.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911206"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.124.267723","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T13:40:33Z","timestamp":1749044433000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.124.267723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":17,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11,1]]},"published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.2967\/jnumed.124.267723"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.124.267723","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,19]]}}}